Terms: = Ovarian cancer AND BCL6, BCL5, 603, 604, ENSG00000113916, ZBTB27, P41182, LAZ3, BCL6A, ZNF51 AND Treatment
24 results:
1. Selectively targeting bcl6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
3. Genome-wide expression profiling reveals novel biomarkers in epithelial ovarian cancer.
Gautam P; Gupta S; Sachan M
Pathol Res Pract; 2023 Nov; 251():154840. PubMed ID: 37844484
[TBL] [Abstract] [Full Text] [Related]
4. Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study.
Sobocan M; Chandrasekaran D; Sideris M; Blyuss O; Fierheller C; Kalra A; Sia J; Miller RE; Mills-Baldock T; Crusz SM; Sun L; Evans O; Robbani S; Jenkins LA; Ahmed M; Kumar A; Quigley M; Lockley M; Faruqi A; Casey L; Brockbank E; Phadnis S; Trevisan G; Singh N; Legood R; Manchanda R
BJOG; 2024 May; 131(6):848-857. PubMed ID: 37752678
[TBL] [Abstract] [Full Text] [Related]
5. Gene-Expression Profiling of Mucinous ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; ; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; ; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ
Clin Cancer Res; 2022 Dec; 28(24):5383-5395. PubMed ID: 36222710
[TBL] [Abstract] [Full Text] [Related]
6. Risk factors for developing peritoneal metastases after curative surgery for colorectal cancer: A systematic review and meta-analysis.
Zhang Y; Qin X; Chen W; Liu D; Luo J; Wang H; Wang H
Colorectal Dis; 2021 Nov; 23(11):2846-2858. PubMed ID: 34411399
[TBL] [Abstract] [Full Text] [Related]
7. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
[TBL] [Abstract] [Full Text] [Related]
8. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
9. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
[TBL] [Abstract] [Full Text] [Related]
10. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.
Bogani G; Apolone G; Ditto A; Scambia G; Panici PB; Angioli R; Pignata S; Greggi S; Scollo P; Delia M; Franchi M; Martinelli F; Signorelli M; Lopez S; Di Donato V; Valabrega G; Ferrandina G; Palaia I; Bergamini A; Bocciolone L; Savarese A; Ghezzi F; Casarin J; Pinelli C; Trojano V; Chiantera V; Giorda G; Sopracordevole F; Malzoni M; Salerno G; Sartori E; Testa A; Zannoni G; Zullo F; Vizza E; Trojano G; Chiantera A; Raspagliesi F
J Gynecol Oncol; 2020 Nov; 31(6):e92. PubMed ID: 33078597
[TBL] [Abstract] [Full Text] [Related]
11. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.
Frey MK; Ellis AE; Zeligs K; Chapman-Davis E; Thomas C; Christos PJ; Kolev V; Prasad-Hayes M; Cohen S; Holcomb K; Blank SV
Am J Obstet Gynecol; 2020 Nov; 223(5):725.e1-725.e9. PubMed ID: 32598911
[TBL] [Abstract] [Full Text] [Related]
12. miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.
Lu J; Wang L; Chen W; Wang Y; Zhen S; Chen H; Cheng J; Zhou Y; Li X; Zhao L
Arch Biochem Biophys; 2019 Jan; 661():1-9. PubMed ID: 30365936
[TBL] [Abstract] [Full Text] [Related]
13. [Non-Hodgkin´s B-lymphoma of the ovaries with an unfavourable prognosis - incidental finding during caesarean section].
Kopáčková M; Beránek P; Bydžovská I; Pytlík R; Soukup J; Mrhalová M
Ceska Gynekol; 2018; 83(1):45-49. PubMed ID: 29510639
[TBL] [Abstract] [Full Text] [Related]
14. [Acute leukemia recurring as extramedullary tumors of the ovary following allogeneic hematopoietic stem cell transplantation].
Imanaka R; Katayama Y; Iwato K; Kyo K; Okatani T; Itagaki M; Katsutani S; Asaoku H
Rinsho Ketsueki; 2018; 59(1):58-63. PubMed ID: 29415939
[TBL] [Abstract] [Full Text] [Related]
15. Current treatment of double hit and double expressor lymphoma.
Reagan PM; Davies A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):295-297. PubMed ID: 29222269
[TBL] [Abstract] [Full Text] [Related]
16. Cost of Care for the Initial Management of ovarian cancer.
Bercow AS; Chen L; Chatterjee S; Tergas AI; Hou JY; Burke WM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Obstet Gynecol; 2017 Dec; 130(6):1269-1275. PubMed ID: 29112648
[TBL] [Abstract] [Full Text] [Related]
17. High expressions of bcl6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
Zhu L; Feng H; Jin S; Tan M; Gao S; Zhuang H; Hu Z; Wang H; Song Z; Lin B
Tumour Biol; 2017 Jul; 39(7):1010428317711655. PubMed ID: 28671040
[TBL] [Abstract] [Full Text] [Related]
18. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract] [Full Text] [Related]
19. Risk of Undetected cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract] [Full Text] [Related]
20. Financial burden of gynecologic-cancer survivors associated with attendance in a surveillance program at a tertiary care hospital in Thailand.
Suprasert P; Manopunya M
Asian Pac J Cancer Prev; 2011; 12(7):1761-3. PubMed ID: 22126561
[TBL] [Abstract] [Full Text] [Related]
[Next]
